White paper on advancing #implementation of #CKM therapies led by @NkiruOsude@cbgranger et al in @AmericanHeartJ
Wonderful to see seasoned implementation scientists or investigators who’ve led high-touch implementation RCTs / projects on author panel.
https://t.co/yRlTYZiRaa
When cardiovascular medicines should be discontinued
- for the prevention of potential harm
- for a lack of benefit
- for the availability of better alternatives.
Our #deprescribing review has just been published in @ESC_Journals@cbgranger@DCRINews
https://t.co/zht0fUANsT
ACC 23 Late-breaking Discussion with @NPagidipati & @cbgranger:COORDINATE-Diabetes Trial
Multifaceted intervention⬆️prescription of 3 groups of evidence-based therapies
Publication: https://t.co/Op61FmQbkE
#LBCT#ACC23#WCCardio#laSECtelleva#DIabetes
https://t.co/4kvXBhwKCQ
#ACC23 🔥Late-breaking Discussion
Join Drs @hvanspall, @NPagidipati & @cbgranger as they discuss the #COORDINATE-Diabetes trial👉 https://t.co/jQhM0o61Na
Coordinated, multifaceted intervention ⬆️ prescription of 3 groups of evidence-based therapies in adults with #T2DM & #ASCVD
RNA-targeted therapeutics in CVD: the time is now!
We tried to provide an update on several exciting developments in the field of RNA-targeted therapeutics in CVD - focus on lipids, anticoagulation, TTR amyloidosis and hypertension. #siRNA#ASO
https://t.co/uUrLZKPA8c
Time to treatment in STEMI is critical and we are not meeting our goals! We need to refocus efforts! https://t.co/LyQQGrlDup via @JAMA_current part of @JAMANetwork. Congrats to Dr Jamie Jollis & @cbgranger@AKjacobsBUMC on this study. Proud to be part of such an amazing team!